What research has led to the development of AtremoPlus?

Degeneration of the organism and L-dopa

The degeneration linked to aging can be accelerated according to certain predispositions or environmental factors, such as pollution or stress. Experts estimate that we lose an average of 10% of dopaminergic neurons per decade and this from our 20 years with a decrease in our motor and cognitive faculties. Over time, the consequences of this degradation of the organism can be tremendous and be accompanied by a series of binding problems.

Oxidation of the body and Vitamin E

The aging of our organism is a complex process. Experts in this field have been studying for a few decades the fundamental reasons for this degeneration. In order to understand aging and study the possibility of slowing it down, a multitude of scientific teams around the world have carried out a very significant number of studies. Oxidative stress clearly crystallizes as one of the main vectors of the aging process. Indeed, it causes damage in our body through free radicals that attack the cells of the organism. Vitamin E then plays an essential role in the protection of cells, and more particularly of their membranes. This vitamin is not produced by our body and present in several foods and in particular some vegetables and oil oils.

A nutritional intake of 10 mg to 50 mg per day depending on age and sex is recommended. In 2012, the European health authorities (EFSA European Food Safety Authority and the European Commission) estimated that an intake of Vitamin E can contribute to the protection of cells against free radicals (antioxidant effects).

The targets of the scientific team

Slow down the degenerative processes related to age

One of the priorities of the scientific team: the development of a solution to support the body in its fight against aging and to slow down the degenerative processes linked to age.

Combat age-related motor problems

The other major objective: promoting life quality in the event of age-related motor problems such as rigidity, slowness of movement, tremors, imbalances, but also cognitive problems.

Develop a well-tolerated solution of natural origin

Finally, another important objective affirmed by the team has always been to be able to offer a solution of 100% natural origin that is very well tolerated by the body.

Preclinical studies and clinical studies

Significant results

Various preclinical studies and clinical studies have been carried out and published during the last few years. The significant results of these scientific studies thus open the way to an innovative and natural approach for age-related problems and more specifically to dopaminergic deficits. The results of studies and the clinical trial carried out in excellent scientific standards confirm these choices: AtremoPlus was tolerated by 100% of the participants, with no undesirable side effects observed. Further studies have to be done to confirm these results over a very long period and with an increasing number of participants, but these findings are extremely encouraging at this stage. 

Publication in scientific journals

The studies have been published (and commented) in the scientific journals below:

1. " Journal of Genomic Medicine and Pharmacogenomics ". 2016 (Clinical trial)
2. " Journal of Exploratory Research in Pharmacology " 2016
3. " Clinical & Medical Biochemistry " 2016
4. " Journal of Nutrition & Food Sciences " 2016
5.  "Alzheimers Disiease and Dementia"  2016
6. " Royal Society of Chemistry " (book: Anti-aging Drugs: From Basic Research to Clinical Practice/A. Vaiserman/chapter 5.6.2) 2016
7. " International Journal of Molecular Science " 2017 (Clinical trial)
8. " Current pharmaceutical design " 2017
9. " CNS Neuroscience & Therapeutics " 2017
10. " Acta Biomed " 2017 (comment)
11. " International Journal of Molecular Science " 2018
12. " Current Medicinal Chemistry " 2018
13.  " Studies in Natural Products Chemistry " 2018 (book)
14. " Planta med " 2019 (Clinical Trial)
15.  " Current Topics in Medicinal Chemistry" 2019
16.  " Current Neuropharmacology " 2019
17.  " Journal of Pharmaceutical Research International " 2019 (comment)
18.  " Current Pharmacogenomics and Personalized Medicine " 2020
19.  " Neuroscience Letters " 2020 (comment)
20.  " Nutrients" 2020
21.  " International Journal of Molecular Science " 2020
22.  " Drug Development Research " 2021
23. " Medicinal Research Reviews" 2021 (Clinical Trial)
24. " Nutraceuticals " 2021
25. " Faba Bean: Chemistry, Properties and Functionality" 2022 (book)
26.  " Medicinal Plants for Cosmetics, Health and Diseases " 2022 (book)
27.  " International Journal of Molecular Science " 2022
28.  " Brain Sciences "  2022 (comment)
29.  " Neuroendocrinology "  2022 (comment)
30.  " Life "  2022
31.  " Arabian Joural of Biochemistry "  2022
32.  "Epigenetics of stress and stress disorders "  2022 (chapter book)
33.  " Ageing Research Reviews "  2023 (comment)
34. " Pharmaceuticals" 2023
35.  " Genes " 2023
36.  " Biology " 2023
37.   " Molecular Science " 2023
38.   " Salud, Ciencia et tecnologia " 2023
39.  " Medicina " 2023
40.  " Brain sciences " 2023
41.  " Neurosciences " 2023 (comment)
42. " Expert Opinon on Drug Metabolism & Toxicology " 2023

The results were also presented at the following scientific conferences:
« 6th conference on Predictive, Preventive and Personalized Medicine & Molecular  Diagnostics » Phoenix, USA 2016
« Drug Discovery and Therapy World Congress 2016 », Boston USA 2016
« 13th World congress of biological Psychiatry », Copenhagen 2017
« 7th conference on predictive, preventive and personalized medicine & molecular diagnostics » Chicago USA, 2017